Recent Approvals in the Management of Plaque Psoriasis

Now Viewing

EP: 1.Recent Approvals in the Management of Plaque Psoriasis

EP: 2.Clinical Experiences With Bimekizumab

EP: 3.Efficacy and Safety of Bimekizumab in Plaque Psoriasis

EP: 4.Efficacy and Safety of Spesolimab and Deucravacitinib

EP: 5.Nonsteroidal Topical Treatments for Plaque Psoriasis

EP: 6.Pediatric Plaque Psoriasis Treatment and Considerations for Patients With Skin of Color

EP: 7.Looking Ahead for the Management of Plaque Psoriasis

EP: 8.Key Takeaways For the Management of Plaque Psoriasis

This is a video synopsis of a discussion involving Mark Lebwohl, MD, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in Manhattan, New York, and Saakshi Khattri, MD, a board-certified dermatologist, rheumatologist, and internist at the same institution.

The discussion, titled "Navigating PSO Progress: A Year in Review," provides a comprehensive review of recent advancements in plaque psoriasis treatment, focusing on key therapeutic approvals from 2023. Dr. Khattri highlights the emergence of various treatments for psoriasis, including topical non-steroidal options like tapinarof, roflumilast, the oral molecule deucravacitinib, and the systemic biologic bimekizumab targeting IL-17A and F.

Dr. Lebwohl emphasizes the remarkable efficacy of bimekizumab, noting its unprecedented ability to achieve PASI 100 in over 50% of patients, a feat previously unseen in psoriasis treatment. The discussion also touches on the drug's rapid onset of action, particularly in arthritis patients.

Both panelists express enthusiasm for bimekizumab's impact on patient outcomes and its potential as a game-changer in dermatological practice. Dr. Khattri shares her experience of using bimekizumab successfully in patients who had previously failed other treatments, underscoring its significance in clinical practice.

Video synopsis is AI-generated and reviewed by Dermatology Times® editorial staff.